<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-113268</identifier>
<setSpec>0210-4806</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Treatment of prostate and renal cancer with oral drugs (abiratarone and antiangiogenic agents): Positioning statement from the Spanish Association of Urology</dc:title>
<dc:description xml:lang="en">No disponible</dc:description>
<dc:creator>Mata, J</dc:creator>
<dc:creator>Valle, J. I. del</dc:creator>
<dc:creator>Esteban, M</dc:creator>
<dc:creator>Arrabal, M</dc:creator>
<dc:creator>Mateos, J</dc:creator>
<dc:creator>Malet, J. M</dc:creator>
<dc:creator>Elizalde, A</dc:creator>
<dc:creator>Hernández, C</dc:creator>
<dc:creator>Cruz, N</dc:creator>
<dc:creator>Reina, C</dc:creator>
<dc:creator>Gutiérrez, E</dc:creator>
<dc:creator>Cózar, J. M</dc:creator>
<dc:creator>Cabo, M. de</dc:creator>
<dc:creator>Villavicencio, H</dc:creator>
<dc:creator>Artiles, J. L</dc:creator>
<dc:creator>Extramiana, J</dc:creator>
<dc:creator>Jiménez-Cidre, M</dc:creator>
<dc:creator>Caffaratti, J</dc:creator>
<dc:creator>Gómez, A</dc:creator>
<dc:creator>Miguélez, E</dc:creator>
<dc:creator>Nalda, L. M</dc:creator>
<dc:creator>Unda, M</dc:creator>
<dc:creator>Rodríguez-Antolín, A</dc:creator>
<dc:creator>Prieto, L</dc:creator>
<dc:creator>Álvarez-Ossorio, J. L</dc:creator>
<dc:creator>Lledó, E</dc:creator>
<dc:creator>Angulo, J. C</dc:creator>
<dc:creator>Server, G</dc:creator>
<dc:creator>Solsona, E</dc:creator>
<dc:creator>Ozonas, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">No disponible</dc:description>
<dc:source>Actas Urol Esp;37(6): 321-323, jun. 2013.</dc:source>
<dc:identifier>ibc-113268</dc:identifier>
<dc:title xml:lang="es">Tratamiento del cáncer de próstata y cáncer renal con fármacos orales (abiraterona y antiangiogénicos): posicionamiento de la Asociación Española de Urología</dc:title>
<dc:subject>^d11914^s22057</dc:subject>
<dc:subject>^d11911^s22074</dc:subject>
<dc:subject>^d19291^s22074</dc:subject>
<dc:subject>^d34460^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d7855^s22057</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d32835^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201306</dc:date>
</metadata>
</record>
</ibecs-document>
